查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
系统性红斑狼疮市场报告：2030 年趋势、预测与竞争分析
市场调查报告书
商品编码
1356928

系统性红斑狼疮市场报告：2030 年趋势、预测与竞争分析

Systemic Lupus Erythematosus Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

系统性红斑狼疮的趋势与预测

预计到 2030 年，全球系统性红斑狼疮市场预计将达到 28 亿美元，2024 年至 2030 年年复合成长率为 6.6%。这个市场的主要驱动因素是自体免疫疾病的盛行率不断上升、公众对发炎自体免疫疾病的认识不断提高以及全球老年人口的增加。全球系统性红斑狼疮市场前景广阔，零售药局、医院和线上药局市场蕴藏商机。

系统性红斑狼疮市场洞察

  • Lucintel 预测，口服药物，包括易于给药的小分子药物，通常用于治疗 SLE，在预测期内将继续成为最大的细分市场，并且患者的偏好不断增加。看来是这样。
  • 由于人们越来越偏好购买处方药，医院预计在预测期内仍将是该市场的最大细分市场。
  • 由于其强大的医疗基础设施和主要企业的存在，北美仍然是最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球系统性红斑狼疮市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球系统性红斑狼疮市场趋势（2018-2023）与预测（2024-2030）
  • 按药物类别分類的全球系统性红斑狼疮市场
    • NSAID
    • 抗疟药
    • 皮质类固醇
    • 免疫抑制剂
    • 生技药品
  • 按给药途径的全球系统性红斑狼疮市场
    • 口服
    • 静脉
    • 皮下的
  • 全球系统性红斑狼疮市场（依最终用途）
    • 零售药房
    • 医院
    • 网路药房
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球系统性红斑狼疮市场按地区划分
  • 北美系统性红斑狼疮市场
  • 欧洲系统性红斑狼疮市场
  • 亚太系统性红斑狼疮市场
  • 其他区域系统性红斑狼疮市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按药物类别分類的全球系统性红斑狼疮市场成长机会
    • 按给药途径分類的全球系统性红斑狼疮市场成长机会
    • 全球系统性红斑狼疮市场成长机会（依最终用途）
    • 全球系统性红斑狼疮市场成长机会（按地区）
  • 全球系统性红斑狼疮市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球系统性红斑狼疮市场的产能扩张
    • 全球系统性红斑狼疮市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • Roche
  • Sanofi
  • GlaxoSmithKline
  • Pfizer
  • Bayer
  • Astra Zeneca
  • Novartis
简介目录

Systemic Lupus Erythematosus Trends and Forecast

The future of the global systemic lupus erythematosus market looks promising with opportunities in the retail pharmacy, hospital, and online pharmacy markets. The global systemic lupus erythematosus market is expected to reach an estimated $2.8 billion by 2030 with a CAGR of 6.6% from 2024 to 2030. The major drivers for this market are increasing incidence of autoimmune diseases, rising public awareness regarding inflammatory autoimmune disorders, and growing number of geriatric population in worldwide.

A more than 150-page report is developed to help in your business decisions.

Systemic Lupus Erythematosus by Segment

The study includes a forecast for the global systemic lupus erythematosus by drug class, route of administration, end use, and region.

Systemic Lupus Erythematosus Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • NSAIDs
  • Antimalarials
  • Corticosteroids
  • Immunosuppressants
  • Biologics

Systemic Lupus Erythematosus Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Intravenous
  • Subcutaneous

Systemic Lupus Erythematosus Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Retail Pharmacies
  • Hospitals
  • Online Pharmacies
  • Others

Systemic Lupus Erythematosus Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Systemic Lupus Erythematosus Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies systemic lupus erythematosus companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the systemic lupus erythematosus companies profiled in this report include-

  • Roche
  • Sanofi
  • GlaxoSmithKline
  • Pfizer
  • Bayer
  • Astra Zeneca
  • Novartis

Systemic Lupus Erythematosus Market Insights

  • Lucintel forecasts that oral will remain the largest segment over the forecast period due to its growing preference among patients as it includes small molecule medications that are easy to administer and remains commonly used treatment for SLE.
  • Within this market, hospital will remain the largest segment over the forecast period due to growing preference for this facility to purchase prescribed drugs.
  • North America Will remain the largest region due to existence of robust healthcare infrastructure and presence of key players in the region.

Features of the Global Systemic Lupus Erythematosus Market

  • Market Size Estimates: Systemic lupus erythematosus market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Systemic lupus erythematosus market size by drug class, route of administration, end use, and region. in terms of value ($B).
  • Regional Analysis: Systemic lupus erythematosus market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different drug classes, route of administrations, end uses, and region.s for the systemic lupus erythematosus market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the systemic lupus erythematosus market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the systemic lupus erythematosus market size?

Answer: The global systemic lupus erythematosus market is expected to reach an estimated $2.8 billion by 2030.

Q.2. What is the growth forecast for systemic lupus erythematosus market?

Answer: The global systemic lupus erythematosus market is expected to grow with a CAGR of 6.6% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the systemic lupus erythematosus market?

Answer: The major drivers for this market are increasing incidence of autoimmune diseases, rising public awareness regarding inflammatory autoimmune disorders, and growing number of geriatric population in worldwide.

Q.4. What are the major segments for systemic lupus erythematosus market?

Answer: The future of the systemic lupus erythematosus market looks promising with opportunities in the retail pharmacy, hospital, and online pharmacy markets.

Q.5. Who are the key systemic lupus erythematosus market companies?

Answer: Some of the key systemic lupus erythematosus companies are as follows:

  • Roche
  • Sanofi
  • GlaxoSmithKline
  • Pfizer
  • Bayer
  • Astra Zeneca
  • Novartis

Q.6. Which systemic lupus erythematosus market segment will be the largest in future?

Answer: Lucintel forecasts that oral will remain the largest segment over the forecast period due to its growing preference among patients as it includes small molecule medications that are easy to administer and remains commonly used treatment for SLE.

Q.7. In systemic lupus erythematosus market, which region is expected to be the largest in next 5 years?

Answer: North America Will remain the largest region due to existence of robust healthcare infrastructure and presence of key players in the region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the systemic lupus erythematosus market by drug class (NSAIDs, antimalarials, and corticosteroids, immunosuppressants, and biologics), route of administration (oral, intravenous, and subcutaneous), end use (retail pharmacies, hospitals, online pharmacies, and others)and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Systemic Lupus Erythematosus Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Systemic Lupus Erythematosus Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Systemic Lupus Erythematosus Market by Drug Class
    • 3.3.1: NSAIDs
    • 3.3.2: Antimalarials
    • 3.3.3: Corticosteroids
    • 3.3.4: Immunosuppressants
    • 3.3.5: Biologics
  • 3.4: Global Systemic Lupus Erythematosus Market by Route of Administration
    • 3.4.1: Oral
    • 3.4.2: Intravenous
    • 3.4.3: Subcutaneous
  • 3.5: Global Systemic Lupus Erythematosus Market by End Use
    • 3.5.1: Retail Pharmacies
    • 3.5.2: Hospitals
    • 3.5.3: Online Pharmacies
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Systemic Lupus Erythematosus Market by Region
  • 4.2: North American Systemic Lupus Erythematosus Market
    • 4.2.1: North American Systemic Lupus Erythematosus Market by Route of Administration: Oral, Intravenous, and Subcutaneous
    • 4.2.2: North American Systemic Lupus Erythematosus Market by End Use: Retail Pharmacies, Hospitals, Online Pharmacies, and Others
  • 4.3: European Systemic Lupus Erythematosus Market
    • 4.3.1: European Systemic Lupus Erythematosus Market by Route of Administration: Oral, Intravenous, and Subcutaneous
    • 4.3.2: European Systemic Lupus Erythematosus Market by End Use: Retail Pharmacies, Hospitals, Online Pharmacies, and Others
  • 4.4: APAC Systemic Lupus Erythematosus Market
    • 4.4.1: APAC Systemic Lupus Erythematosus Market by Route of Administration: Oral, Intravenous, and Subcutaneous
    • 4.4.2: APAC Systemic Lupus Erythematosus Market by End Use: Retail Pharmacies, Hospitals, Online Pharmacies, and Others
  • 4.5: ROW Systemic Lupus Erythematosus Market
    • 4.5.1: ROW Systemic Lupus Erythematosus Market by Route of Administration: Oral, Intravenous, and Subcutaneous
    • 4.5.2: ROW Systemic Lupus Erythematosus Market by End Use: Retail Pharmacies, Hospitals, Online Pharmacies, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Systemic Lupus Erythematosus Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Systemic Lupus Erythematosus Market by Route of Administration
    • 6.1.3: Growth Opportunities for the Global Systemic Lupus Erythematosus Market by End Use
    • 6.1.4: Growth Opportunities for the Global Systemic Lupus Erythematosus Market by Region
  • 6.2: Emerging Trends in the Global Systemic Lupus Erythematosus Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Systemic Lupus Erythematosus Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Systemic Lupus Erythematosus Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Roche
  • 7.2: Sanofi
  • 7.3: GlaxoSmithKline
  • 7.4: Pfizer
  • 7.5: Bayer
  • 7.6: Astra Zeneca
  • 7.7: Novartis